Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Zacks News
Is Vertex Pharmaceuticals (VRTX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
Regeneron (REGN) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Regeneron (REGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $274.34, marking a +1.29% move from the previous day.
Vertex's Kalydeco Wins Approval in EU for CF in Children
by Zacks Equity Research
Vertex's (VRTX) Kalydeco gains EU nod for use in cystic fibrosis patients aged from six months to 18 years with the R117H mutation in the CFTR gene.
Looking for Earnings Beat? Play These 5 Stocks
by Sanghamitra Saha
Invest in top-ranked stocks that are likely to beat their earnings estimates in the upcoming releases.
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $272.82, moving -1.51% from the previous trading session.
Zacks Market Edge Highlights: Vertex Pharmaceuticals, Channel Advisor, Gold Fields, AngloGold Ashanti and Dropbox
by Zacks Equity Research
Zacks Market Edge Highlights: Vertex Pharmaceuticals, Channel Advisor, Gold Fields, AngloGold Ashanti and Dropbox
5 Strong Buy Growth Stocks for this Secular Bull Rally
by Tracey Ryniec
How can the stock market be near another all-time high with a pandemic and 40 million unemployed? Secular bull markets don't care about headlines.
Zacks.com featured highlights include: Vertex Pharmaceuticals, Dollar General, CVS Health and Tractor Supply
by Zacks Equity Research
Zacks.com featured highlights include: Vertex Pharmaceuticals, Dollar General, CVS Health and Tractor Supply
4 Stocks That Flaunt an Impressive Interest Coverage Ratio
by Sumit Singh
Interest coverage ratio is used to determine how effectively a company can pay the interest charged on its debt.
3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity
by Benjamin Rains
Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...
Why Is Vertex (VRTX) Up 10.4% Since Last Earnings Report?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights include: BJs Wholesale Club, Fortinet, Vertex Pharmaceuticals, SPS Commerce and Repligen
by Zacks Equity Research
Zacks.com featured highlights include: BJs Wholesale Club, Fortinet, Vertex Pharmaceuticals, SPS Commerce and Repligen
VRTX vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
VRTX vs. ILMN: Which Stock Is the Better Value Option?
Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
Profit From 5 Stocks Likely to Beat on Earnings
by Sanghamitra Saha
Bet on five stocks that are likely to outdo earnings estimates.
S&P Reclaims 3,000: Buy 6 Stocks With More Than 25% Growth
by Sweta Killa
In the latest market rally driven by hopes surrounding potential coronavirus vaccines and reopening of the economy, the S&P 500 reclaimed its 3,000 level and is poised to rise further.
2 Top Factors Buoy Wall Street Since Memorial Day: 5 Picks
by Tirthankar Chakraborty
As optimism surrounding a coronavirus vaccine and consumer activity begin to pick up, Wall Street is expected to trade higher.
Dr. Reddy's (RDY) Q4 Earnings Increase Y/Y, Revenues Beat
by Zacks Equity Research
Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.
The Zacks Analyst Blog Highlights: Chegg, Quidel, MarketAxess, Dropbox and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chegg, Quidel, MarketAxess, Dropbox and Vertex Pharmaceuticals
The Zacks Analyst Blog Highlights: Chegg, Nautilus Group, Sprouts Farmers Market, VeriSign and Vertex Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chegg, Nautilus Group, Sprouts Farmers Market, VeriSign and Vertex Pharmaceuticals
The Zacks Analyst Blog Highlights: The Hain Celestial Group, Murphy USA, Vertex Pharmaceuticals, Sprouts Farmers Market and ASE Technology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: The Hain Celestial Group, Murphy USA, Vertex Pharmaceuticals, Sprouts Farmers Market and ASE Technology
Vertex Pharmaceuticals, Align Technology, Walmart, Home Depot and Target highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Vertex Pharmaceuticals, Align Technology, Walmart, Home Depot and Target highlighted as Zacks Bull and Bear of the Day
5 Reasons Why Growth Stocks Will Soar Further
by Sanghamitra Saha
A few positive developments on the vaccine front, unprecedented economic help, reopening of economies and some bullish economic datapoints should facilitate growth stocks ahead.
Major Indexes Defying "Sell in May" Adage: 5 Growth Picks
by Nalak Das
Half of this month is already over, yet Wall Street is in green defying the well-known financial-world adage "Sell in May and go away."